Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs TTP 273 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms LOGRA
- Sponsors vTv Therapeutics LLC
- 11 Jun 2019 Results of post hoc analysis of patients from the LOGRA study assessing efficacy of TTP273 on patients with stage 2 hypertension presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 07 Sep 2017 According to a vTv Therapeutics media release, additional data will be presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD).